Abstract

A female patient with substantial history and physical findings of Ehlers-Danlos syndrome by systematic evaluation had a variant in the gene encoding the sixth subunit of mitochondrial ATP synthetase gene that produced a change from glycine to aspartic acid at position 132 of the MT-ATP6 protein (MT-ATP6 m.8921G>A, p.Gly132Asp). The mutation was heteroplasmic, affecting 32% of the mitochondria in blood leucocytes, was qualified as a pathogenic variant because of its significant molecular change, but was not detected in the maternal blood sample as might be expected for its low degree of heteroplasmy. The patient was shown to have typical findings of Ehlers-Danlos syndrome by comparison of 48 history and physical findings in her and a peer group of 32 teenage females with that diagnosis. None of the classical neurosensory or developmental symptoms of mitochondrial disease were present in mother or daughter, but the patient had symptoms, metabolite alterations during rest or exercise, and muscle biopsy changes that suggested mild mitochondrial dysfunction. She also had heterozygous variants of uncertain significance in the nuclear PLOD1, FLNA, and ATP2A genes by concomitant whole exome sequencing that could also contribute to her arthritis-adrenaline disorder. Mitochondrial dysfunction is proposed to influence neuromuscular components of connective tissue, acting through an articulo-autonomic dysplasia cycle to cause the typical joint-skin laxity and dysautonomia of Ehlers-Danlos syndrome.

Highlights

  • Genomic testing is dramatically expanding the numbers of genes associated with disease, when applied to more common disease spectra like Ehlers-Danlos syndrome (EDS) and other heritable disorders of connective tissue (Malfait, et al, 2017; Tinkle and Levy, 2019; Weerakkody, et al, 2016; Wilson, 2015; Wilson, 2019a)

  • A female patient with substantial history and physical findings of Ehlers-Danlos syndrome by systematic evaluation had a variant in the gene encoding the sixth subunit of mitochondrial ATP synthetase gene that produced a change from glycine to aspartic acid at position 132 of the MT-ATP6 protein (MT-ATP6 m.8921G>A, p.Gly132Asp)

  • Flexibility was recognized by her parents early on and by the patient, especially when various adolescent sports activities were limited by pain and fatigue—mainly progressive motor fatigue with muscle cramping

Read more

Summary

Introduction

Genomic testing is dramatically expanding the numbers of genes associated with disease, when applied to more common disease spectra like Ehlers-Danlos syndrome (EDS) and other heritable disorders of connective tissue (Malfait, et al, 2017; Tinkle and Levy, 2019; Weerakkody, et al, 2016; Wilson, 2015; Wilson, 2019a). The genetic component can be examined by NextGen or massive parallel DNA sequencing (Teer and Mullikin, 2010; Yang, et al, 2013; Wilson, 2014) This technology simultaneously determines the DNA nucleotide sequence of all targeted genomic regions in the manner of reading all book pages at once rather than beginning to end. The combined approach allows timely and affordable detection of protein/RNA-coding changes that may be associated with disease

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call